| Suche Service: |
|
Popular Städte Zürich Basel Winterthur Bern Luzern St. Gallen Genève Lugano Thun Frauenfeld Neuchâtel Schaffhausen Chur Zug Fribourg La Chaux-De-Fonds Dübendorf Olten Vevey Bellinzona |
|
Anzeige: |
| Anzeige: |
8952 Schlieren Wagistrasse 21
Esbatech Ag Karte
Esbatech Ag
Telefon: (044) 733 49 00
Webseite (esbatech.ch)
Anzeige:
anästhesiologie, drugs, yeast, biotech, pharmaceutical research, laboratory, pharmaceutical products, chemische industrie hersteller, drugs testing, drugs research, human antibodies, highly stable antibody fragments, functional screenings, biotechnology
Dienstleistung Kategorien
anästhesiologie drugs yeast biotech pharmaceutical research laboratory pharmaceutical products chemische industrie hersteller drugs testing drugs research human antibodies highly stable antibody fragments functional screenings biotechnologyBezogene Services
Anzeige:ESBATech AG The ;Company Products ;& ;Technologies PR ;and ;Publications Career About ESBATech
People
Intellectual Property
Directions
Contact
Drug Discovery
Drug Development
Company News
Scientific Publications
Upcoming Events
PR Contact
Why ESBATech
Positions
To apply
Webmail
;
ESBATech, an Alcon Biomedical Research Unit
; ESBATech is a Zurich, Switzerland based Biomedical Research Unit of Alcon . The company has been acquired by Alcon, the world leader in Ophthalmology, on September 14, 2009. ESBATech lays the foundation for Alcon to move into biotechnology. Prior to the acquisition, ESBATech focused on advancing therapeutic antibody fragments in ophthalmology but also other fields. All rights outside of ophthalmology were spun-out to Delenex Therapeutics.
;
;
People
Intellectual Property
Directions
Contact
Drug Discovery
Drug Development
Company News
Scientific Publications
Upcoming Events
PR Contact
Why ESBATech
Positions
To apply
Webmail
;
ESBATech, an Alcon Biomedical Research Unit
; ESBATech is a Zurich, Switzerland based Biomedical Research Unit of Alcon . The company has been acquired by Alcon, the world leader in Ophthalmology, on September 14, 2009. ESBATech lays the foundation for Alcon to move into biotechnology. Prior to the acquisition, ESBATech focused on advancing therapeutic antibody fragments in ophthalmology but also other fields. All rights outside of ophthalmology were spun-out to Delenex Therapeutics.
;
;
Anzeige: